Loading
Some T-cell-receptor drugs only work in people with a particular immune 'tissue type'. About half of people of European ancestry have it; far fewer in some other populations.
Tebentafusp, brenetafusp, and afamitresgene autoleucel recognise peptides presented on HLA-A*02:01, so eligibility requires a blood test. Frequencies vary from ~45-50% in Europeans to under 20% in some African and East Asian populations, creating an equity problem that next-generation TCR agents against other alleles aim to address.
Backbone ribbon from PDB 1IGT. RCSB PDB 1IGT. The ribbon widens where the chain is folded into a regular pattern and narrows where it is a loose loop.
No public structure of tebentafusp; intact IgG shown as reference.
Showing the molecule this term concerns: Tebentafusp.
The glossary entry explains the word; the readout page carries the scoring rule, the thresholds approvals use, the companion diagnostics and the tests.
Shares HLA-A*02:01 (HLA typing for TCR therapies), Brenetafusp, Afamitresgene autoleucel, PRAME.
Shares SS18::SSX fusion (synovial sarcoma), Afamitresgene autoleucel, TCR-T cell therapy, Antigen presentation & immune editing.
Shares Tebentafusp, TCR-T cell therapy, Antigen presentation & immune editing, Uveal melanoma.
Shares Brenetafusp, PRAME, T-cell engagers (bispecific), Melanoma.
Shares Brenetafusp, PRAME, Tebentafusp, Uveal melanoma.
Shares Tebentafusp, TCR-T cell therapy, T-cell engagers (bispecific), Melanoma.
Shares Brenetafusp, Tebentafusp, T-cell engagers (bispecific).
Shares Tebentafusp, Uveal melanoma, T-cell engagers (bispecific), Melanoma.